by | Jun 26, 2024 | Publications
South Asian J Cancer. 2024 Feb 12;13(2):126-131. doi: 10.1055/s-0043-1761441. eCollection 2024 Apr. ABSTRACT Karuna JhaBackground Multiple myeloma is a cytogenetically heterogeneous, evolving, and incurable disease. Differences in prevalence of myeloma already exist...
by | Jun 26, 2024 | Publications
J Blood Med. 2024 Jun 21;15:285-290. doi: 10.2147/JBM.S468921. eCollection 2024. ABSTRACT Immune checkpoint inhibitor-related thrombocytopenia (irTCP) is a relatively rare immune-related adverse event (irAE); however, overall survival may worsen when it occurs....
by | Jun 26, 2024 | Publications
Pharmacoeconomics. 2024 Jun 25. doi: 10.1007/s40273-024-01399-3. Online ahead of print. ABSTRACT BACKGROUND AND OBJECTIVE: Multiple myeloma is a rare incurable hematological cancer in which most patients relapse or become refractory to treatment. This systematic...
by | Jun 26, 2024 | Publications
World J Surg Oncol. 2024 Jun 25;22(1):168. doi: 10.1186/s12957-024-03453-y. ABSTRACT BACKGROUND: To investigate the prognosis of patients with Multiple Myeloma (MM) after surgery, analyze the risk factors leading to adverse postoperative outcomes, and establish a...
by | Jun 25, 2024 | Publications
Clin Exp Med. 2024 Jun 25;24(1):136. doi: 10.1007/s10238-024-01398-w. ABSTRACT Dysregulated lipid metabolism in the bone marrow microenvironment (BMM) plays a vital role in multiple myeloma (MM) development, progression, and drug resistance. However, the exact...
by | Jun 25, 2024 | Publications
Clin Nucl Med. 2024 Jun 25. doi: 10.1097/RLU.0000000000005326. Online ahead of print. ABSTRACT Extramedullary myelomatous disease is an aggressive condition where clonal plasma cells proliferate outside the bone marrow, allowing independent survival. This state is...
